Open Access iconOpen Access

REVIEW

Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics

KAI WANG2,#, FENGTIAN ZHANG1,3,4,#, CHANGLONG WEN5, ZHIHUA HUANG6, ZHIHAO HU1, YUWEN ZHANG1, FUQIANG HU2,*, LIJUAN WEN1,6,*

1 Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou, 341000, China
2 College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China
3 Department of Orthopedics, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China
4 Medical College of Soochow University, Suzhou, 215123, China
5 Department of Infectious Diseases, Ganzhou People’s Hospital, Ganzhou, 341000, China
6 Ganzhou Key Laboratory of Neuroinflammation Research, Gannan Medical University, Ganzhou, 341000, China

* Corresponding Author: FUQIANG HU. Email: email; LIJUAN WEN. Email: Lijuan Wen
# These authors contributed equally to this work

Oncology Research 2021, 29(5), 351-363. https://doi.org/10.32604/or.2022.025696

Abstract

The blood-brain barrier (BBB) is an essential component in regulating and maintaining the homeostatic microenvironment of the central nervous system (CNS). During the occurrence and development of glioblastoma (GBM), BBB is pathologically destroyed with a marked increase in permeability. Due to the obstruction of the BBB, current strategies for GBM therapeutics still obtain a meager success rate and may lead to systemic toxicity. Moreover, chemotherapy could promote pathological BBB functional restoration, which results in significantly reduced intracerebral transport of therapeutic agents during multiple administrations of GBM and the eventual failure of GBM chemotherapy. The effective delivery of intracerebral drugs still faces severe challenges. However, strategies that regulate the pathological BBB to enhance the transport of therapeutic agents across the barrier may provide new opportunities for the effective and safe treatment of GBM. This article reviews the structure and function of BBB in physiological states, the mechanisms underlying BBB pathological fenestration during the development of GBM, and the therapeutic strategies of GBM based on BBB intervention and medicinal drugs transporting across the BBB.

Keywords


Cite This Article

APA Style
WANG, K., ZHANG, F., WEN, C., HUANG, Z., HU, Z. et al. (2021). Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics. Oncology Research, 29(5), 351-363. https://doi.org/10.32604/or.2022.025696
Vancouver Style
WANG K, ZHANG F, WEN C, HUANG Z, HU Z, ZHANG Y, et al. Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics. Oncol Res. 2021;29(5):351-363 https://doi.org/10.32604/or.2022.025696
IEEE Style
K. WANG et al., "Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics," Oncol. Res., vol. 29, no. 5, pp. 351-363. 2021. https://doi.org/10.32604/or.2022.025696



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1326

    View

  • 650

    Download

  • 0

    Like

Share Link